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Miami, May 8, 2006
Dear Editor,
We read with interest the report by Loureiro &
Rozenfeld on the epidemiology of sickle cell disease
hospital admissions in Brazil.2 In this article, the au-
thors reported median age at death in three Brazilian
regions of 26.5 years, 30 years, and 31.5 years. They
then compared these summaries with Jamaican me-
dian survival rates of 53 years for men and 58.5 years
for women,4 and reported ”an early lethality” reflect-
ing ”social inequalities that exist between Brazil and
other countries”.
In assuming the equivalence of median survival and
median age at death, -the authors have made a simple
error that is common in the epidemiological literature.
Median survival is defined as the age at which 50% of
the study population has died, and must additionally
include participants that do not die. These living par-
ticipants are accounted for using statistical techniques
that remove or ”censor” the live participant at their
last known contact date within a study window.
In the Jamaican report, homozygous sickle cell (SS)
disease was studied over a 10-year period, during
which 290 out of 3,301 (8.8%) patients died. In the
same paper, median age at death was reported as 24.9
years for men, and 25.7 years for women. These fig-
ures for Jamaicans with SS disease are directly com-
parable with, and broadly similar to the reported me-
dian ages at death in Bahia, Rio de Janeiro, and São
Paulo. The dataset reported by Loureiro and Rozenfeld
does not allow the calculation of median survival. It
remains possible that median survival is similar to
those identified in Jamaica and the USA.3
In a later paper from the Jamaican group it is shown
that, in the absence of newborn screening for sickle
cell disease, almost 65% of children affected by SS
disease and not identified at birth will not benefit
from important early-life clinical intervention.1 It is
therefore likely that early deaths, even if they oc-
curred in hospital, are not ascribed to SS disease, and
this possibly leads to an optimistic median age at
death when relying on hospital-based data.
In the coming decades more accurate information on
median survival in homozygous sickle-cell disease
will become available from patient groups such as
the Jamaican Cohort Study, in which patients are iden-
tified at birth and prospectively followed. Until then,
survival estimates will depend on the appropriate-
ness of techniques used and assumptions made.
Klaas J. J. Wierenga
Dr. John T. Macdonald Foundation Center for Medical Genetics
University of Miami, Miami, USA
Ian R. Hambleton
Chronic Disease Research Centre, Tropical Medicine Research Institute,
University of the West Indies, Bridgetown, Barbados, West Indies
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Rio de Janeiro, June 17, 2006
Dear Editor,
In reference to the letter from Dr Wierenga and Dr
Hambleton, we agree with them in respect to their
statement that median survival cannot be straightly
compared to median age at death, as we have written
in our article. However, as we estimated a very low
age at death in these patients, we improperly con-
cluded that there were differences in survival between
countries, explaining the differences by social in-
equalities. Our data did not allow this comparison.
The median survival in Brazilian sickle disease may
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be similar to other countries estimates but unfortu-
nately we have no awareness of any cohort study in
Brazil on this subject. In fact, the age at death be-
tween Jamaica and Brazil can be comparable.
We thank the authors for their remarks and we expect
to give notice on Brazilian sickle disease epidemiol-
ogy soon.
Monique M. Loureiro
Suely Rozenfeld
Escola Nacional de Saúde Pública,
Fundação Oswaldo Cruz
This article has received corrections in agreement with the ERRATUM published in Volume 40 Number 5.
